☆ 4.6 Letter

Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'

NATURE REVIEWS CLINICAL ONCOLOGY (2018)

Get Full Text
Add to Collection

Journal

NATURE REVIEWS CLINICAL ONCOLOGY
Volume 15, Issue 4, Pages -

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/nrclinonc.2018.20

Keywords

-

Categories

Oncology

Funding

  1. Bristol-Myers Squibb
  2. Celgene
  3. Cellectis
  4. Kite Pharma
  5. Merck
  6. Poseida Therapeutics
  7. Janssen
  8. Abbvie
  9. ADC Therapeutics
  10. Genentech
  11. Incyte
  12. Pharmacyclics
  13. Pfizer
  14. Seattle Genetics
  15. Servier
  16. Verastem
  17. Daichi-Sanky
  18. Karyopharm
  19. Sunesis

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.